No abstract

Oral cancer is the 11th common malignancy in the world among all cancers in 2018, with a prevalence of 2.8% and 1.3% for men and women respectively (Ghantous & Abu Elnaaj, 2017; Worldwide_can-cer_data, 2018). The World Health Organization (WHO) has reported that an estimated 657,000 new cases of oral cavity and pharynx cancers occur each year, with more than 330,000 deaths annually (WHO & Retrieved, 2019). In Taiwan, the Taiwan Ministry of Health Statistics (TMHS) reports that oral cancer ranks fifth among the top ten cancer deaths and fourth in male cancer incidence and deaths, and the incidence and mortality rate among men is nearly 10 times that of women (TMHS & Retrieved, 2019). Incidence and mortality have increased year by year while patients' ages at onset have gradually decreased. The percentage of patients receiving early oral cancer treatment is relatively high, with a five-year survival rate as high as 70%-80% and a cure rate of 80% or more (Coleman, 2012; NCI & Retrieved, 2019; Shah & Gil, 2009). Early diagnosis and identification of patients at high risk are considered essential to help ensure early treatment and to improve the response to therapy, and oral cancer patients' prognosis and overall survival (Chakraborty,